Thanks to all who were able to join us for "Shattering the Glass Ceiling"
CU Innovations hosted a successful event highlighting the achievements of women in innovation on our medical campus. This free event was offered to the University of Colorado community and featured presentations from women innovators as well
as a panel discussion, networking opportunities, with lunch to follow. We hope you enjoyed learning from and connecting with leading women in the field of medical innovation.
Event Speakers & Panelists
Shelia Violette, PhD
Co-founder, Chief Scientific Officer & President of Research
Q32Bio
Shelia Violette, co-founder, Chief Scientific Officer and President of Research of Q32 Bio, is a scientific and industry leader in the field of inflammation, autoimmunity and fibrosis. She advanced Q32 Bio from a seed stage company and through Series B funding to become a clinical stage company with two programs in clinical development. In her more than 30 years of industry experience, she has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 100 manuscripts and patents.
Prior to co-founding Q32 Bio, she was an Entrepreneur in Residence at Atlas Venture evaluating new company opportunities. Preceding her role at Atlas, Shelia served in leadership roles in the Immunology Research group at Biogen, joining Stromedix as Vice President of Research and returning to Biogen as Vice President of Research, spearheading the tissue injury and fibrosis therapeutic area. She also has directed research and led therapeutic programs at several biotechnology companies including Repligen and Ariad. She received her Ph.D. in Pharmacology from Yale University.
Event Moderators
Shelia Violette, PhD
Co-founder, Chief Scientific Officer & President of Research
Q32Bio
Shelia Violette, co-founder, Chief Scientific Officer and President of Research of Q32 Bio, is a scientific and industry leader in the field of inflammation, autoimmunity and fibrosis. She advanced Q32 Bio from a seed stage company and through Series B funding to become a clinical stage company with two programs in clinical development. In her more than 30 years of industry experience, she has provided strategic and operational leadership to multi-disciplinary teams of scientists, led several research and early clinical programs, and authored more than 100 manuscripts and patents.
Prior to co-founding Q32 Bio, she was an Entrepreneur in Residence at Atlas Venture evaluating new company opportunities. Preceding her role at Atlas, Shelia served in leadership roles in the Immunology Research group at Biogen, joining Stromedix as Vice President of Research and returning to Biogen as Vice President of Research, spearheading the tissue injury and fibrosis therapeutic area. She also has directed research and led therapeutic programs at several biotechnology companies including Repligen and Ariad. She received her Ph.D. in Pharmacology from Yale University.